by
1
Department of General and Specialized Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
2
Beth Israel Deaconess Medical Center, Anesthesia and Intensive Care Department, Harvard Medical School, Boston, MA 02215, USA
3
Department of Anesthesia and Intensive Care, School of Medicine, The University of Jordan, Amman 11942, Jordan
4
Department of Emergency Medicine and Accidents, School of Medicine, The University of Jordan, Amman 11942, Jordan
5
Department of Cancer Biology, Wake Forest School of Medicine and Wake Forest Baptist Health, Winston-Salem, NC 27157, USA
6
School of Medicine, Mutah University, Karak 61710, Jordan
7
Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
*
Author to whom correspondence should be addressed.
DOI: https://doi.org/10.3390/vaccines9111223
PDF: https://www.mdpi.com/2076-393X/9/11/1223/pdf
Abstract
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.